Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Genprex Inc (GNPX)
Genprex Inc (GNPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,058
  • Shares Outstanding, K 51,979
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,740 K
  • 60-Month Beta -0.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.63
Trade GNPX with:

Options Overview Details

View History
  • Implied Volatility 377.30% ( -9.48%)
  • Historical Volatility 89.43%
  • IV Percentile 77%
  • IV Rank 24.29%
  • IV High 1,419.14% on 11/16/22
  • IV Low 43.08% on 10/18/22
  • Put/Call Vol Ratio 0.03
  • Today's Volume 639
  • Volume Avg (30-Day) 173
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 7,624
  • Open Int (30-Day) 6,605

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.11
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7225 +43.94%
on 05/17/23
1.0600 -1.89%
on 06/02/23
+0.2598 (+33.30%)
since 05/02/23
3-Month
0.7225 +43.94%
on 05/17/23
1.1800 -11.86%
on 03/03/23
-0.1199 (-10.34%)
since 03/02/23
52-Week
0.7225 +43.94%
on 05/17/23
2.6700 -61.05%
on 08/16/22
-0.4000 (-27.78%)
since 06/02/22

Most Recent Stories

More News
Genprex (NASDAQ: GNPX) Receives Approval to Advance to Phase 2 of REQORSA(R) Trial

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is reporting results from the phase 1 portion of its Acclaim-1...

GNPX : 1.0400 (+11.35%)
Genprex (NASDAQ: GNPX) Announces Results of Phase 1 Trial Will Be Published at ASCO Meeting

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is reporting on positive data gathered from the phase...

GNPX : 1.0400 (+11.35%)
Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

GNPX : 1.0400 (+11.35%)
Genprex (NASDAQ: GNPX) Announces Video Featuring CMO Discussing Positive Preclinical Data

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today released a new video where the company’s Chief...

GNPX : 1.0400 (+11.35%)
Genprex (NASDAQ: GNPX) to Present at Upcoming May Industry Conferences

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced its participation in upcoming...

GNPX : 1.0400 (+11.35%)
Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual Meeting

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

GNPX : 1.0400 (+11.35%)
Independent Researchers Find That TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

GNPX : 1.0400 (+11.35%)
Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies

/PRNewswire/ -- Rodney Varner, CEO of Genprex, Inc. ("Genprex" or the "Company") (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing...

GNPX : 1.0400 (+11.35%)
Genprex to Present at Bioprocessing Summit Conference

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

GNPX : 1.0400 (+11.35%)
Genprex to Participate in March Investor and Industry Conferences

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

GNPX : 1.0400 (+11.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small...

See More

Key Turning Points

3rd Resistance Point 1.1532
2nd Resistance Point 1.1066
1st Resistance Point 1.0733
Last Price 1.0400
1st Support Level 0.9934
2nd Support Level 0.9468
3rd Support Level 0.9135

See More

52-Week High 2.6700
Fibonacci 61.8% 1.9261
Fibonacci 50% 1.6963
Fibonacci 38.2% 1.4664
Last Price 1.0400
52-Week Low 0.7225

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar